Vera Therapeutics (VERA) Q2 2026 earnings summary

Executive summary

• TRUTAKNA received accelerated FDA approval in July 2026 for adults with primary IgA nephropathy (IgAN) at risk for disease progression, showing a 46% reduction in proteinuria and a 42% reduction vs. placebo at 36 weeks in the ORIGIN 3 trial; final efficacy data expected Q3 2026 and potential full approval in 2027.

• Early market reception for TRUTAKNA has been encouraging, with the company positioning it as a foundational therapy for IgAN due to its unique dual inhibition of BAFF and APRIL.

• Pipeline includes MAU868 (Phase 2 completed for BK virus) and VT-109 (preclinical BAFF/APRIL inhibitor); expanding indications for atacicept in other autoimmune kidney diseases.

• Leadership transition announced: Nancy Boman, M.D., Ph.D. appointed Chief Regulatory Officer, succeeding William Turner.

Financial highlights

• Net loss of $109.5M for Q2 2026, up from $76.5M in Q2 2025; net loss per share was $1.52 versus $1.20 year-over-year.

• Operating expenses rose to $112.5M in Q2 2026 (up 40% YoY), driven by higher R&D and G&A costs, including $15M milestone payment and commercial launch investments.

• Cash, cash equivalents, and marketable securities totaled $499.2M as of June 30, 2026, down from $714.6M at year-end 2025.

• Net cash used in operating activities for the first six months of 2026 was $206.8M, compared to $109.2M for the same period in 2025.

• Stockholders’ equity was $407.8M as of June 30, 2026, down from $604.5M at year-end 2025.

Outlook and guidance

• Cash runway expected to fund operations for at least 12 months from June 2026.

• Final ORIGIN 3 efficacy data and supplemental BLA submission for TRUTAKNA expected in Q3 and Q4 2026, respectively.

• Additional PIONEER clinical results are expected in Q4 2026, and potential full approval of TRUTAKNA in IgAN is targeted for 2027.

• Anticipate increased R&D and G&A expenses as commercial and clinical activities expand.